{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/6846e583cca944a48e6715d3/6ae9e055dc2860cef4a5dfda?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"CPHI Milan 2026 Newsbeat: Quotient Sciences Takes AI Into A Clinical Trial - Andy Lewis","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/6846e583cca944a48e6715d3/1793712151001-29736188-903a-4753-8836-9b8a8fba3ccb.jpeg?height=200","description":"<p>Register your interest for 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&amp;utm_medium=referral&amp;utm_campaign=hln27cpw-cl-arto</p><p><br></p><p>Quotient Sciences has announced interim results from its AI-driven clinical trial. After three years developing AI for formulation development, with 30 to 50% time savings, Quotient took the approach into the clinic to see if it could also learn how a formulation&#39;s composition relates to its performance in people.</p><p><br></p><p>On Newsbeat, live at CPHI Milan 2026, Ruby Collier spoke to Andy Lewis, Chief Scientific Officer of Quotient Sciences, about the results and what they could mean for drug development.</p><p><br></p><p>In this episode, Andy covers:</p><p><br></p><p>(00:25) The interim results: the AI appears to have learned the link between composition and in vivo performance after testing just three prototypes, which could reduce the clinical testing a product needs.</p><p><br></p><p>(01:25) How the algorithm learned: active learning with Bayesian optimisation, starting untrained, trained first on in vitro data and then on the emerging clinical data, with a safety committee reviewing every formulation it requested. When the team changed the target to rule out luck, it hit that one too.</p><p><br></p><p>(03:27) What it could mean for modified release products: fewer formulation screens, faster clinical development, and an in silico model of the drug product, like a digital twin, that could support scale-up and post-approval changes such as a change of site.</p><p><br></p><p>(05:05) What drug developers at CPHI Milan are most excited about: a first look at the pharmacokinetic data, and how the tool&#39;s visualisations map onto quality by design.</p><p><br></p><p>Watch the full episode to hear how Quotient Sciences is using AI to save time at every step of drug product development.</p><p><br></p><p>Follow ARTO</p><p><br></p><p>LinkedIn: https://www.linkedin.com/company/artotalent/</p><p>Spotify: https://open.spotify.com/show/1cSZVJ63yXJ3kqnVORyTbw</p><p>Instagram: https://www.instagram.com/arto.talent</p><p>TikTok: https://www.tiktok.com/@artotalent</p><p>Apple Podcasts: https://podcasts.apple.com/gb/podcast/making-it-in-manufacturing/id1819731245</p><p>Website: https://arto-talent.com/</p><p>Youtube: https://www.youtube.com/@artotalent</p><p><br></p><p>Andy Lewis</p><p>LinkedIn: https://www.linkedin.com/in/andylewis1/</p><p><br></p><p>Ruby Collier</p><p>LinkedIn: https://www.linkedin.com/in/ruby-collier/</p><p><br></p><p>Timestamps:</p><p>00:00 Introduction</p><p>00:16 Quotient&#39;s interim clinical trial results</p><p>01:25 How the algorithm learned from each dosing period</p><p>03:27 What it could mean for modified release development</p><p>05:05 What drug developers at CPHI are excited about</p><p>06:08 Closing thoughts</p><p><br></p><p>#Newsbeat #ARTOTalent #CPHI #CPHIMilan #AI #MachineLearning #FormulationDevelopment #DrugDevelopment #ClinicalTrials</p>","author_name":"ARTO Talent"}